Anrotinib is used to treat locally advanced or metastatic non-small cell lung cancer.
Anrotinib is a small molecule, multi-targeted receptor tyrosine kinase inhibitor indicated as a single agent for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that has progressed or relapsed after receiving at least 2 prior systemic chemotherapies.
Anrotinib hydrochloride, which is reformulated from its marketed counterpart sorafenib, exerts antitumor effects by inhibiting tumor neoangiogenesis and growth and proliferation signaling pathways.
It has been demonstrated that in advanced non-small cell lung cancer where existing treatments are ineffective or have failed, amlotinib significantly improves overall survival relative to the placebo group.
The more common adverse reaction to amlotinib is rash, which is well tolerated by most patients. Other adverse reactions such as hypertension, proteinuria, diarrhea, abdominal pain, nausea, vomiting, and loss of appetite can also occur. The most serious adverse reaction to Anrotinib is bleeding.
If you need to use Anrotinib, do so under the supervision of a physician.